
CLAIMS





































1. A compound of formula (**I-4**) or a pharmaceutically acceptable salt thereof,






























Formula (**I-4**).

wherein


$\mathbf{R^2}$ is chloro;

$\mathbf{R^b}$ is selected from the group consisting of , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .


, (e.g.,  or ), , , , , , , , , , , , , , , , , , , , , , , , , , , and ; and

$\mathbf{R^d}$ is CH_3.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein $\mathbf{R^b}$ is

.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein $\mathbf{R^b}$ is

.

4. The compound of claim 1, selected from the group consisting of:

Compound No. 161;

Compound No. 185;

Compound No. 200;

Compound No. 204;

Compound No. 205;

Compound No. 210;

Compound No. 211;

Compound No. 214;

Compound No. 216;

Compound No. 217;

Compound No. 218;

Compound No. 225;

Compound No. 226;

Compound No. 232;

Compound No. 236;

Compound No. 237;

Compound No. 238;

Compound No. 242;

Compound No. 244;

Compound No. 245;

Compound No. 246;

Compound No. 247;

Compound No. 303;

Compound No. 305;

Compound No. 306;

Compound No. 307;

Compound No. 311;

Compound No. 312;

Compound No. 314;

Compound No. 317;

Compound No. 318;

Compound No. 322;

Compound No. 323;

Compound No. 324;

Compound No. 325;

Compound No. 329;

Compound No. 331;

Compound No. 332;

Compound No. 336;

Compound No. 339;

Compound No. 341;

Compound No. 342;

Compound No. 345;

Compound No. 349;

Compound No. 352;

Compound No. 366;

Compound No. 372;

Compound No. 378;

Compound No. 402;

Compound No. 403;

Compound No. 409;

Compound No. 410;

Compound No. 413;

Compound No. 414;

Compound No. 415;

Compound No. 416;

Compound No. 417;

Compound No. 426;

Compound No. 429;

Compound No. 439;

Compound No. 441;

Compound No. 443;

Compound No. 444;

Compound No. 448;

Compound No. 457;


Compound No. 464;

Compound No. 467; and

Compound No. 471,


or a pharmaceutically acceptable salt thereof.

5. A compound that is:




or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5, wherein the compound is:



or a pharmaceutically acceptable salt thereof.


7. The compound of claim 5, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

8. The compound of any of claims 5-7, wherein the compound exists in a racemic mixture.

9. A compound that is:



or a pharmaceutically acceptable salt thereof.

10. The compound of claim 5 in a crystalline form, wherein an XRPD pattern comprises peaks at about 16.5±0.5, 17±0.5 and 17.8±0.5 degrees two-theta using copper K-alpha radiation.

11. The crystalline form of claim 10, wherein the XRPD pattern further comprises peaks at about 14±0.5, and 19.5±0.5 degrees two-theta using copper K-alpha radiation.

12. The crystalline form of claim 11, wherein the XRPD pattern further comprises peaks at 21.5-23, 25.5-27, 27-28 and 29.5-31 degrees two-theta using copper K-alpha radiation.

13. A pharmaceutical composition comprising the compound of any one of claims 1-12 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

14. The pharmaceutical composition of claim 13, comprising the compound of any of claims 1-12.


15. The pharmaceutical composition of claim 13, comprising the compound of any of claims 5-7.

16. Use of the compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disorder caused by or associated with VAV1 polymorphisms in a subject in need thereof, wherein a therapeutically effective amount of the medicament is to be administered to the subject.




17. The use of claim 16, wherein the disorder is an autoimmune disorder selected from the group consisting of multiple sclerosis, rheumatoid arthritis, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, diabetes type I or II, and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, psoriasis, Graves ophthalmopathy, alopecia areata and others, allergic diseases (e.g., allergic asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, allergic contact dermatitis), inflammatory diseases optionally with underlying aberrant reactions (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis, intrinsic asthma, inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury), atherosclerosis, osteoarthritis, irritant contact dermatitis and further eczematous dermatitis, seborrheic dermatitis, cutaneous manifestations of immunologically-mediated disorders, inflammatory eye disease, keratoconjunctivitis, myocarditis or hepatitis.



18. The compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof for use in therapy.




19. A process for manufacturing compound that is:








, the process comprising:



(i) coupling a compound of formula  and a compound of formula  to form a compound  ; followed by


(ii) borylating the compound  to form  (Intermediate I);

(iii) reacting a compound  with a compound  to form a compound  ; followed by

(iv) performing a deprotection of the compound  to form a compound  ; followed by

(v) reacting the compound  with a compound  to form a compound  ; followed by

(vi) performing a cyclization of the compound  to provide  (Intermediate II); and

(vii) coupling Intermediate I and Intermediate II to provide 

.